BDBM102343 US10562854, No. B9::US8536181, B9::US9278930, B9

SMILES Oc1c(CN2CCN(Cc3ccccc3)CC2)ccn(Cc2ccccc2)c1=O

InChI Key InChIKey=YIROCWNERWBGFO-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 102343   

TargetEgl nine homolog 1(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US10562854, No. B9 | US8536181, B9 | US9278930, B9)
Affinity DataIC50:  1.70E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US10562854, No. B9 | US8536181, B9 | US9278930, B9)
Affinity DataIC50:  1.26E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US10562854, No. B9 | US8536181, B9 | US9278930, B9)
Affinity DataIC50:  1.70E+4nMpH: 7.5Assay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US10562854, No. B9 | US8536181, B9 | US9278930, B9)
Affinity DataIC50:  1.26E+4nMAssay Description:VEGF: HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following ove...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US10562854, No. B9 | US8536181, B9 | US9278930, B9)
Affinity DataIC50:  1.70E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US10562854, No. B9 | US8536181, B9 | US9278930, B9)
Affinity DataIC50:  1.26E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US10562854, No. B9 | US8536181, B9 | US9278930, B9)
Affinity DataIC50:  1.70E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US10562854, No. B9 | US8536181, B9 | US9278930, B9)
Affinity DataIC50:  1.26E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent